Xatger 10 mg prolonged release tablets

  • Name:

    Xatger 10 mg prolonged release tablets

  • Company:
    info
  • Active Ingredients:

    alfuzosin hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/10/16

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/10/2016
print

Print ViewKeyword Search SmPC

Gerard Laboratories

Gerard Laboratories

Company Products

Medicine NameActive Ingredients
Medicine Name Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets Active Ingredients Abacavir hydrochloride, Lamivudine
Medicine Name Agerdex 1mg Film Coated Tablets Active Ingredients Anastrozole
Medicine Name Agomelatine Mylan 25 mg film-coated tablets Active Ingredients Agomelatine
Medicine Name Amisulpride 50mg & 200mg Tablets Active Ingredients Amisulpride
Medicine Name Amlodipine Mylan 5mg & 10mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Amlodipine/Valsartan Mylan 5mg/80mg, 5mg/160mg, 10mg/160mg film-coated tablets Active Ingredients Amlodipine besilate, Valsartan
Medicine Name Areloger 7.5mg & 15mg Tablets Active Ingredients Meloxicam
Medicine Name Aripil 5mg & 10mg Film-coated Tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Atazanavir Mylan 300 mg hard capsules Active Ingredients Atazanavir sulfate
Medicine Name Atenetic 50/12.5mg & 100/25mg Film - coated Tablets Active Ingredients Atenolol, Chlortalidone
Medicine Name Atorvastatin Mylan 10 mg, 20 mg, 40 mg & 80 mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate
Medicine Name Atovaquone/Proguanil Hydrochloride 250 mg/100 mg film-coated tablets Active Ingredients Atovaquone, Proguanil Hydrochloride
Medicine Name Azromax 250mg Film-coated tablets Active Ingredients Azithromycin monohydrate
Medicine Name Baclopar Tablets 10 mg Active Ingredients Baclofen
Medicine Name Bisoprolol Mylan Active Ingredients Bisoprolol Fumarate
Medicine Name Brabio 20mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Brabio 40mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Cifloxager 250 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Cifloxager 500 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciprager 10mg & 20mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprager 40mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprofloxacin Mylan 2mg/1ml solution for infusion Active Ingredients Ciprofloxacin
Medicine Name Clopidogrel Mylan 75 mg film-coated tablets Active Ingredients clopidogrel hydrochloride
Medicine Name Darunavir Mylan 800 mg film-coated tablets Active Ingredients darunavir ethanolate
Medicine Name Depreger 50mg & 100mg Film-Coated Tablets Active Ingredients sertraline hydrochloride
1 - 0 of 117 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 October 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 18 October 2016 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

6.5 Nature and contents of container
PVC/PVDC-aluminium blister.

10, 20, 30, 30x1, 50, 60, 60x1, 90, 100 tablets

Not all pack sizes may be marketed.

Updated on 12 October 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 12 October 2016 PIL

Reasons for updating

  • Change to date of revision
  • Introduction of new pack/pack size

Updated on 13 November 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
  • protease inhibitors, clarithromycin, telithromycin and nefazodone since alfuzosin blood levels are increased (see section 5.2).
  • Patients being treated with alfuzosin must be haemodynamically stable before treatment with a phosphodiesterase-5 inhibitor (sildenafil, tadalafil, vardenafil) is initiated.

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

section 2:

Excipient with known effect:

Each tablet contains 7.6 mg lactose (as lactose monohydrate).

 

For the full list of excipients, see section 6.1.



section 4.1
Treatment of moderate to severe functional symptoms of benign prostatic hyperplasia (BPH).-

section 4.2

Posology

 

Adults

 One 10 mg prolonged-release tablet once daily. The first dose should be taken at bedtime. The tablet should be taken immediately after the same meal each day.

 

Paediatric population

The safety and efficacy of alfuzosin have not been demonstrated in children aged 2 to 16 years (see section 5.1). Therefore, alfuzosin is not indicated for use in paediatric population.


Patients with reduced renal function

Mild to moderate renal insufficiency

If a lower dose is not sufficient, therapy can be adjusted to one 10 mg prolonged-release tablet daily according to clinical response.

Patients with hepatic insufficiency


Method of administration

For oral use.

 

The prolonged-release tablet should be swallowed whole with a sufficient amount of fluid (see section 4.4).



section 4.4

Patients with severe renal impairment


Risk of hypotension


In coronary patients, the specific treatment for coronary insufficiency should be continued, taking into account that the concomitant administration of nitrates and alfuzosin may increase the risk of occurrence of hypotension. If angina pectoris reappears or worsens, alfuzosin should be discontinued.


Pronounced drop in blood pressure has been reported in post-marketing surveillance in patients with pre-existing risk factors (such as underlying cardiac disease and/or concomitant treatment with anti-hypertensive medication). The risk of developing hypotension and related adverse reactions may be greater in older people

There is a risk of cerebral ischaemic disorders in patients with symptomatic or asymptomatic pre-existing cerebral circulatory disturbances, due to the fact that hypotension may develop following alfuzosin administration (see section 4.8).



Previous history of hypersensitivity to other alpha1-receptor blockers

Treatment should be initiated gradually in patients with hypersensitivity to other alpha1-receptor blockers.

Cardiac failure

As with all alpha1-receptor blockers, alfuzosin should be used with caution in patients with acute cardiac failure.


QTc prolongation


Intraoperative Floppy Iris Syndrome

The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha1-receptor blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the operation, the surgeon should be informed of current or past alpha1-receptor blocker use and prepare for possible modifications to their surgical technique.

 

Tablet administration


Lactose

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

section 4.5
  • protease inhibitors, clarithromycin, telithromycin and nefazodone since alfuzosin blood levels are increased (see section 5.2).
  • Patients being treated with alfuzosin must be haemodynamically stable before treatment with a phosphodiesterase-5 inhibitor (sildenafil, tadalafil, vardenafil) is initiated.

 

Ketoconazole

Repeated 200 mg daily dosing of ketoconazole, for seven days resulted in a 2.1-fold increase in Cmax and a 2.5-fold increase in exposure of xatger 10 mg prolonged-release tablets when administered under fed conditions. Other parameters such as tmax and t1/2 were not modified.

 

The increase in alfuzosin Cmax and AUC(last) following repeated 400 mg daily administration of ketoconazole was 2.3-fold and 3.2-fold respectively (see section 5.2).


section 4.6

FertilityNo data are available.



section 4.8: table

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.



section 4.9

Symptoms

Hypotension, reflex tachycardia.

 

Management

section 5.1
Drugs used in benign prostatic hypertrophy, alpha-adrenoreceptor antagonists,

 

Mechanism of action


Pharmacodynamic effects


Clinical efficacy and safety

 

Benign Prostatic Hypertrophy (BPH)


Acute urinary retention (AUR) related to BPH

Alfuzosin has been shown to increase the chances of successful spontaneous urination at first episode of acute urinary retention (AUR) related to BPH and in the following six months after this episode, reducing the requirement for surgery.

 

In a double-blind placebo-controlled study including 357 patients, alfuzosin 10 mg daily increased the success rate of spontaneous urination after catheter removal in men over 65 years.

 

88 patients (56.1%) in alfuzosin group had successful urination, while 30 patients (35.7%) in the placebo treatment had successful urination (p = 0.003).

 

165 patients who achieved successful urination during the first phase were included in the second phase and were re-examined: alfuzosin reduced the risk of surgery (both emergency surgery due to recurrence of AUR or as non-emergency) compared to placebo with a risk reduction of respectively 61%, 52%, and 29% at 1, 3 and 6 months of treatment with alfuzosin.


section 5.2

Absorption

 The maximal plasma concentration is achieved 9 hours after administration.

 

Studies have shown that consistent pharmacokinetic profiles are obtained when the product is administered after a meal.

 

After the first dose (fed) the mean maximum plasma concentration was 7.72 ng/ml, AUCinf was 127 ng x h/ml (fed), and tmax was 6.69 h (fed). Under steady state conditions (fed) the mean AUC over the dosing interval (AUCτ) was 194 (SD = 75) ng x h/ml, mean Cmax was 13.6 (SD = 5.6) ng/ml and Cmin was 3.1 (SD = 1.6) ng/ml.

Biotransformation

Alfuzosin is extensively metabolised in the liver (through various routes). None of the metabolites are pharmacologically active.

 

Metabolic interactions: CYP3A4 isoform is the principal hepatic enzyme involved in the metabolism of alfuzosin (see section 4.5).


Alfuzosin metabolites are eliminated via renal excretion and probably also via biliary excretion.


Linearity/non-linearity

Alfuzosin has linear pharmacokinetic properties within the therapeutic dose range.

 

Renal or hepatic impairment

Compared to subjects with normal renal function, mean Cmax and AUC values are moderately increased in patients with renal impairment, without modification of the apparent elimination half-life. This change in the pharmacokinetic profile is not considered clinically relevant with creatinine clearance >30ml/min.



Updated on 3 November 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to how the medicine works
  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 1 July 2015 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 13 February 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to further information section
  • Change to date of revision

Updated on 3 August 2012 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

section 4.2 uopdated to include:

Paediatric population:

Efficacy of Xatger has not been demonstrated in children aged 2 to 16 years

(see section 5.1). Therefore, Xatger is not indicated for use in paediatric

population.

section 5.1 updated to include:

Paediatric population

Xatger is not indicated for use in the paediatric population (see section 4.2).

 

Efficacy of alfuzosin hydrochloride was not demonstrated in the two studies

conducted in 197 patients 2 to 16 years of age with elevated detrusor leak point

pressure (LPP≥40 cm H2O) of neurologic origin. Patients were treated with alfuzosin

hydrochloride 0.1 mg/kg/day or 0.2 mg/kg/day using adapted paediatric formulations.


Updated on 31 July 2012 PIL

Reasons for updating

  • Change to information about pregnancy or lactation

Updated on 30 July 2012 PIL

Reasons for updating

  • Change of contraindications
  • Change to date of revision

Updated on 27 March 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 26 March 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

section 4.4 Special warnings and precautions for use
added:

Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of Xatger.

Updated on 13 July 2011 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 11 July 2011 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC uploaded on IPHA following approval of MR Renewal.

Section 5.2 Pharmacokinetic properties

Paragraph 'Alfuzosin has linear pharmacokinetic properties etc....' was repeated so removed one paragraph.

Section 9 Date of Authorisation/Renewal of the Authorisation

included date of last renewal: 5th September 2010

Section 10 Date of revision of the text

updated to April 2011

Updated on 6 July 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 12 March 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 March 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 Variations approved to update SPC section 4.2, 4.4 (include Intraoperative Floppy Iris Syndrome) 5.2 and 10 and consequential changes to the Package Leaflet.

Updated on 11 March 2008 PIL

Reasons for updating

  • Change to dosage and administration
  • Change to warnings or special precautions for use
  • Change due to user-testing of patient information

Updated on 15 February 2008 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 14 August 2007 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 udpated SmPC in line with variation approval to increase shelf life to 4 years

Updated on 19 April 2007 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)